Canaccord reiterates Hold on Illumina stock amid Roche competition

📌 Key Takeaways

• Canaccord maintains a Hold rating on Illumina stock.
• The rating is influenced by competition from Roche.
• The analysis suggests a neutral outlook for Illumina's stock performance.
• Market dynamics in the genomics sector are a key consideration.

🏷️ Themes

Stock Rating, Market Competition

Entity Intersection Graph

No entity connections available yet for this article.

Source

investing.com